The decision drew criticism from experts who said that the development company had not proven that the drug slows down cognitive ability.
US regulators have granted conditional approval for the first new Alzheimer’s drug in nearly twenty years.
The Food and Drug Administration (FDA) has approved the antibody-based drug aducanumab, developed by Biogen, a biotech company.
The drug reduces the amyloid plaques that affect the brains of Alzheimer’s patients.
However, the approval drew sharp criticism from experts, who said that the company has not proven that the drug slows down serious cognitive decline in patients suffering from this disease. The FDA will require Biogen to continue testing the drug after its release and ultimately show that patients actually feel better.